The Medical Letter on Drugs and Therapeutics
Tofacitinib (Xeljanz) for Rheumatoid Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or are intolerant of methotrexate. Ruxolitinib (Jakafi) is the only other JAK inhibitor available in the US; it is FDA-approved for treatment of myelofibrosis.1

TREATMENT OF RHEUMATOID ARTHRITIS — For initial treatment of RA, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD), and add a nonsteroidal anti-inflammatory drug (NSAID) with or without a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice; hydroxychloroquine is a safer alternative that may be appropriate in the mildest cases. Tumor necrosis factor (TNF) inhibitors are typically the first-line biologic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tofacitinib (Xeljanz) for Rheumatoid Arthritis
Article code: 1407a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian